newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from Paragon